Lipid Nanoparticle– tag –
-
Taylor & Francis Unveils Advanced Nanomedicine Strategies Revolutionizing Precision Therapeutics via Bioresponsive Materials, Lipid Nanoparticles, and Metal Nanostructures
Taylor & Francis Online (Article Collection) UK Overview Taylor & Francis has published an article collection highlighting advanced nanomedicine strategies that offer unprecedented control over pharmaceutical agent delivery, revoluti... -
Beam Therapeutics Gains FDA IND Approval for In Vivo Base Editing Therapy BEAM-304 for PKU
CRISPR Medicine News USA Overview Beam Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for BEAM-304, an in vivo base editing therapy targeting phenylketonuria (PKU). This therapy utilizes adenine base editing d... -
Efficient Prime Editing In Vivo and In Vitro Demonstrated with Lipid Nanoparticles: High Efficacy, Low Off-Target Effects
PubMed International Overview Recent research reports the development of an optimized platform for prime editing using lipid nanoparticles (PE-LNP), demonstrating high gene editing efficiency in vivo. This LNP-based system offers a compe... -
University of Houston Discovers ‘Salt-Loaded LNPs’ to Overcome Major Gene Therapy Obstacle by Enhancing Endosomal Escape
University of Houston USA Overview Researchers at the University of Houston have made a groundbreaking discovery to improve intracellular delivery of genetic material, a major hurdle in gene therapy. They developed 'salt-loaded lipid nan... -
Beam Therapeutics Secures FDA IND Clearance for Liver-Targeted LNP Formulation BEAM-304 as PKU Treatment, Phase 1/2 Trial Imminent
Business Wire / Nasdaq USA Overview Beam Therapeutics announced FDA Investigational New Drug (IND) clearance for BEAM-304, its lead candidate for Phenylketonuria (PKU). BEAM-304 is a liver-targeted lipid nanoparticle (LNP) formulated bas... -
University of Houston Researchers Discover Salt Significantly Enhances Lipid Nanoparticle Delivery Efficiency in Gene Therapy
University of Houston USA Overview University of Houston researchers have discovered that adding salt to lipid nanoparticles (LNPs) dramatically improves the intracellular delivery efficiency of mRNA vaccines and gene therapeutics. This ... -
Portal Biotechnologies Raises $9M to Expand Cell Engineering Platform, Attracting Merck & Co. and AbbVie
FirstWord HealthTech USA Overview Portal Biotechnologies secured $9 million to advance its cell engineering platform, which has drawn partnerships with Merck & Co. and AbbVie. The platform leverages mechanoporation for efficient intr... -
Intellia Therapeutics Reports “Paradigm-Shifting” Phase 3 Data for Lonvoguran Ziclumeran, Achieving 87% Reduction in HAE Attacks with Single In Vivo CRISPR Dose
Fierce Biotech USA Overview Intellia Therapeutics announced groundbreaking Phase 3 HAELO trial data for lonvoguran ziclumeran (lonvo-z), an *in vivo* CRISPR gene-editing therapy for hereditary angioedema (HAE). This one-time treatment de... -
Broad Institute Achieves Major Breakthrough in Prime Editing: Enhanced In Vivo Delivery with Optimized LNPs Paves Way for Broader Genetic Disease Therapies
Broad Institute USA Overview Researchers at the Broad Institute have significantly improved the efficiency and specificity of prime editing by optimizing its core components and developing an advanced lipid nanoparticle (LNP) delivery sy... -
T-CURX Acquires Germany’s Pantherna Therapeutics to Accelerate LNP-Based In Vivo CAR-T Therapy Development; United Immunity Also Enters In Vivo CAR-M Therapy for Solid Tumors and Fibrotic Diseases
HealthcareNOWradio.com Germany Overview T-CURX acquired Germany-based Pantherna Therapeutics, specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technology, aiming to accelerate in vivo CAR-T therapy development and c...
